Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis.

× No keyword cloud information.

14 in total

1. SEOM clinical guidelines for the treatment of antiemetic prophylaxis in cancer patients receiving chemotherapy.

Authors: Jesús García Gómez; M Eva Pérez López; Jesús García Mata; Dolores Isla Casado
Journal: Clin Transl Oncol Date: 2010-11 Impact factor: 3.405

2. Acute emesis: moderately emetogenic chemotherapy.

Authors: Jørn Herrstedt; Bernardo Rapoport; David Warr; Fausto Roila; Emilio Bria; Cynthia Rittenberg; Paul J Hesketh
Journal: Support Care Cancer Date: 2010-08-02 Impact factor: 3.603

Review 3. Aprepitant: a review of its use in the prevention of nausea and vomiting.

Authors: Monique P Curran; Dean M Robinson
Journal: Drugs Date: 2009 Impact factor: 9.546

Review 4. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults.

Authors: Zhou Likun; Jing Xiang; Ba Yi; Duan Xin; Zheng Liu Tao
Journal: Oncologist Date: 2011-01-31

5. Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting.

Authors: Henning Burmeister; Stefan Aebi; Cristina Studer; Martin F Fey; Oliver Gautschi
Journal: Support Care Cancer Date: 2011-01-14 Impact factor: 3.603

6. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.

Authors: David G Warr; James C Street; Alexandra D Carides
Journal: Support Care Cancer Date: 2010-05-13 Impact factor: 3.603

7. Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.

Authors: Ying Wan; Fanyin Meng; Nan Wu; Tianhao Zhou; Julie Venter; Heather Francis; Lindsey Kennedy; Trenton Glaser; Francesca Bernuzzi; Pietro Invernizzi; Shannon Glaser; Qiaobing Huang; Gianfranco Alpini
Journal: Hepatology Date: 2017-06-19 Impact factor: 17.425

8. Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting.

Authors: Patrick Langford; Paul Chrisp
Journal: Core Evid Date: 2010-10-21

9. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy.

Authors: Paul J Hesketh; Matti Aapro; James C Street; Alexandra D Carides
Journal: Support Care Cancer Date: 2009-09-12 Impact factor: 3.603

10. Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.

Authors: N Bouganim; G Dranitsaris; S Hopkins; L Vandermeer; L Godbout; S Dent; P Wheatley-Price; C Milano; M Clemons
Journal: Curr Oncol Date: 2012-12 Impact factor: 3.677